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Background: There is no agreed definition of ‘difficult asthma’ or what investiga-
tions should be available to investigate these patients. Patients with difficult asthma
remain symptomatic on high levels of treatment and are high users of medical
resources.
Aim: To develop a set of quality indicators for the definition and investigation of
difficult asthma.
Method: Modified RAND Appropriateness Method was used. An expert panel
composed of nine hospital asthma specialists who run ‘difficult’ asthma clinics and
were identified from a shortlist of key workers in the field. Indicators were rated as
necessary to define and investigate difficult asthma.
Results: Difficult asthma was defined as ‘symptoms persisting beyond therapy
consistent with step 4 of the British Thoracic Society (BTS) guidelines’ (high dose
inhaled corticosteroids and long acting b2-agonists). Eighty-three indicators were
identified (40 relating to definition and 43 relating to investigations). Of these 32
(39%) were rated as necessary: 7 out of 40 (18%) for defining difficult asthma and 23
out of 43 (53%) for investigations. Indicators of high medical resource usage wereElsevier Ltd. All rights reserved.
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Defining and investigating difficult asthma: Developing quality indicators 1255characteristic of the ‘difficult’ nature of the management of patient with difficult
asthma. A framework for the investigation of these patients was created.
Conclusion: The listed performance indicators identify a range of requirements that
are necessary to define difficult asthma. Targeting of real needs in this group of
patients will lead to better patient care and reduction of ‘waste’ in provision of
healthcare.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Asthma literature is filled with an array of
terminology to describe patients who remain
symptomatic despite high levels of therapy. These
include severe asthma,1 refractory asthma,2
steroid resistant asthma,3 steroid insensitive asth-
ma,4 therapy resistant asthma,5 persistent asth-
ma,6 difficult-to-treat asthma1 and difficult
asthma7; terms which have often been used
interchangeably. The TENOR study1 recruited
patients who were considered to have severe
or difficult-to-treat asthma. Of this cohort only
48% of patients were felt to have severe
asthma by their physicians leaving half labelled
‘difficult asthma’ with lesser degrees of asthma
severity. The variety of terms that exist need to be
clarified so that all authors can use an agreed
terminology.
Severe asthma refers to those patients with
physiologically severe disease that remains unre-
sponsive to high dose therapy, often implying
regular or frequent oral corticosteroid therapy. A
number of empirical grading scales exist for severe
asthma8–10 on the presumption that it is the only
disease process being measured and is the only
condition causing symptoms. These are based upon
symptoms, fixed physiological criteria and thera-
peutic thresholds.
Difficult asthma refers to asthma of mild,
moderate or severe physiological severity that
may co-exist with another condition, unresponsive
to conventional asthma therapy. This secondary
condition may be structural as in bronchiectasis,
functional as in dysfunctional breathing or vocal
cord dysfunction, or psycho-social in origin. This
secondary condition is responsible for the prolon-
gation of respiratory symptoms which are then
wrongly attributed as being due to asthma. Without
appropriate management of both the asthma and
any other co-morbid condition, these patients
remain symptomatic and become high users of
medical resources with frequent GP attendances
and hospital admissions.11,12 There is often an
escalation of inappropriate therapy when the co-morbid condition goes unrecognised, and the
severity of asthma is over-estimated.
There are a number of specialist asthma clinics in
the UK that accept referrals for difficult or severe
asthma. The results of a structured approach to
assessment of such patients have recently been
published.5,13 These studies are both observational
in nature. Robinson et al. identified that 32% of
patients had alternative or additional diagnoses,
psychiatric illness or non-compliance with therapy.
Heaney et al. made similar observations but went
further by identifying predictors of true therapy
resistance (inhaled corticosteroid dose 42000 mg
BDP equivalent, previous assessment by a respira-
tory specialist and FEV1 at referral o70% pre-
dicted).
It has not been widely agreed which facilities
should be available for the investigation of these
patients and practice is often anecdotal and depen-
dant on local availability. Good-quality evidence
(randomised double blind placebo controlled trials)
does not exist in this field of diagnostic testing due to
the heterogeneity of the patients and subsequent
difficulty in performing sufficiently large trials.
In situations where evidence is sparse or un-
certain14–16 consensus techniques, which explore
consensus among a group of experts by synthesising
opinions in combination with available evidence,
are an increasingly important mechanism for
developing quality indicators.17 This study used a
consensus technique to define ‘difficult asthma’
and to determine which facilities should be avail-
able for the investigation of patients with difficult
asthma.Methods
We used a modified RAND Appropriateness Meth-
od,18,19 which has been described as the only
systematic method of combining expert opinion
and evidence.15 It combines characteristics of both
the Delphi Technique (e.g. postal questionnaire)
and the Nominal Group Technique (e.g. face-to-
face meeting).17
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A list of 83 indicators was generated based on
previous recommendations of the ERS Task Force on
Difficult/Therapy resistant asthma20 and the Pro-
ceedings of the American Thoracic Society Work-
shop on refractory asthma.2 Indicators were
grouped according to two key issues: (1) How
important are certain indices in defining difficult
asthma? (40 indicators) and (2) The importance of
specific investigations in the assessment of difficult
asthma (43 indicators).Expert panel formation
The expert panel was drawn from those clinicians
running severe or difficult asthma clinics in England
and Scotland, authors of key trials and recognised
experts, and was selected to provide geographical
balance throughout the United Kingdom. A shortlist
of 11 panellists was invited to participate. All
agreed but only 9 (82%) were available for the
panel meeting (see Acknowledgements). Panel
sizes between 9 and 12 members provide results
that have been shown to be reproducible by
second panels19 whilst facilitating group discussion
and preventing the group from becoming too
unwieldy.21Round 1–postal round
The list of indicators was sent to each panellist by
post. Panellists were asked, without reference to
each other, to rate the indicators. Standard Likert
scales were used consisting of continuous integer
scales of 1–9, where 1 signified the indicator wasBox 1 Revised rating scales used in the second rou
Rating scale used for diagnosing difficult asthma
9 Pathognomic
7,8 Necessary criteria
4,5,6 Equivocal, unproven or undecided necessit
2,3 Not a necessary criteria
1 No relevance to difficult asthma
Rating scales used to assess the necessity of investig
9 Absolutely necessary for all patients
7,8 Necessary and must be available for all pa
4,5,6 May be useful but not a necessity
2,3 Not routinely necessary for assessment
1 No relevance to difficult asthma assessmenabsolutely unnecessary and 9 meant it was abso-
lutely necessary.Round 2–expert panel meeting
At the meeting panellists were given an anon-
ymised summary of the panel’s first round scores
and each panellist was fed back their own response
from round one for each indicator. Panellists were
given the opportunity to discuss any indicator they
wished to. After discussing the relevant issues,
each indicator was re-rated.
At the panel meeting the standard Likert scale
of 1 (absolutely unnecessary) to 9 (absolutely
necessary) was considered insufficiently sensitive
for rating indicators relating to the issues of
difficult asthma. The panel meeting is a dynamic
process, which allows stem questions and indicators
to be clarified or modified. This process ensures
that any ambiguities of meaning and important
omissions are minimised as recommended by
Baker.22 The Likert scales were discussed and
subsequently refined (Box 1).
The indicators were rated according to the
following terms of reference. ‘Difficult’ is from
the physicians’ perspective, and the indicators
represent an ‘ideal’ rather than what is necessarily
currently available to all physicians.
Consensus was defined as existing where the
median score from the overall panel was 7 or
greater without disagreement.19 Disagreement was
defined as where at least 33% of the panel members
rated in both the upper(7–9) and lower(1–3) tertile.
Indicators rated 8 or 9 in a RAND method have been
found to be more reproducible if the same
indicators were rated by a panel composed ofnd
y
ations in the assessment of difficult asthma
tients
t
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round ratings.Results
Seven out of 40 indicators were rated as necessary
for defining difficult asthma. Difficult asthma was
defined as ‘symptoms [suggestive of asthma]
despite BTS Step 4 therapy’ (Table 1). Other
necessary criteria included unscheduled atten-
dances at general practices and at Accident and
Emergency departments, three indicators relating
to hospital admissions and use of frequent/con-
tinual oral corticosteroids. Thirty indicators were
identified as being equivocal or unnecessary for
defining difficult asthma (Tables 2 and 3).
There was disagreement over two indicators in
the definition of difficult asthma. These were ‘Pre-
bronchodilator FEV1 as percentage of predicted’Table 1 Indicators necessary for the definition of
difficult asthma.
Median panel score
Pathognomic
9 Symptoms despite Step 4 of
BTS Guidelines
Useful criteria
8 None
7 Unscheduled GP
attendances
Accident and Emergency
department attendances
Hospital admissions greater
than 24 h
Number of ICU admissions
Number of ICU admissions
with raised inflation
pressures
Use of frequent/continual
oral corticosteroids
Table 2 Indicators of uncertain relevance in the
definition of difficult asthma.
Median panel score
Equivocal/
unproven
4,5,6 Peak flow patterns or
variability
Disability/QoL score
Presence of co-morbid
psychiatric historyand ‘Fixed airflow obstruction (post-bronchodilator/
post-steroid trial, FEV1/FVCo70%)’.
Twenty-three investigations were rated as ne-
cessary to assess all patients with difficult asthma
(overall panel rating of 47) (Table 4). Of these,
non-physiological indicators were the only two
with an overall panel rating of 9 (assessment of
environment and psychological well-being) with an
assessment of compliance with medication rated
with an overall panel rating of 8. Other investiga-
tions rated with an overall panel rating of 8
included peak flow patterns/variability, flow/vo-
lume loop, plain chest radiograph, and assessment
of vocal cord dysfunction and dysfunctional breath-
ing/hyperventilation. Fifteen other investigations
were rated as being necessarily available for all
patients diagnosed as having difficult asthma.
These included spirometry with reversibility, total
lung capacity, smoking status and bone densiometry
(Table 4).
In addition, 14 investigations were rated as being
equivocal, which should be available, but are not
necessary for all patients, including bronchoscopy
and exercise induced bronchospasm (Table 5).
Six investigations were rated as being not
routinely required for the assessment of difficult
asthma including inhaled allergen challenge, thyr-
oid function and progressive exercise test (for
cardiac disease) (Table 6). There was disagreement
over one indicator relating to ‘induced sputum
differential white cell count’ in the investigation of
difficult asthma. A full list of ratings for all 83
indicators is available.Discussion
Defining difficult asthma
This paper has characterised difficult asthma as
symptoms despite an arbitrary level of therapy (BTS
Step 49) combined with continued unpredictable or
emergency healthcare resource usage. The level of
therapy differs from the ERS definition,20 which had
a treatment threshold of high dose inhaled corti-
costeroids (did not include long acting b2 agonists
or other add-on therapies). This paper has, for the
first time, described the development of a set of
quality indicators for the investigation of patients
with difficult asthma which can now be assessed in
clinical practice.
Whilst this consensus definition of difficult
asthma incorporates most true severe asthma
patients, there are some patients with physiologi-
cally severe asthma, who do not report symptoms,
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Table 3 Indicators that are not necessary in the definition of difficult asthma.
Median panel score
Not necessary
2,3 Pre-bronchdilator FEV1 as percentage of predicted
Fixed airflow obstruction (post-bronchodilator/post-steroid trial, FEV1/
FVCo70%)
Bronchial hyper-reactivity (PC20)
Presence of significant co-morbid chest disease
Blood eosinophilia
Sputum differential white cell count
Response to inhaled allergen challenge
Skin-prick testing
Total IgE estimation
Allergen-specific RAST
Arterial PO2 estimation
Arterial PCO2 estimation (for hypercapnia)
Arterial pH/PCO2 estimation (for hyperventilation)
Bacterial culture/isolation
Bronchoscopic appearances
Airway smooth muscle hypertrophy/hyperplasia on bronchial wall biopsy
Fibroblast accumulation on bronchial wall biopsy
Plain chest radiograph
HRCT evidence of bronchiectasis
HRCT bronchial wall thickening
HRCT ground glass shadowing
3He contrast MRI ventilation defects
Assessment of corticosteroid absorption/efficacy
Use of leukotriene antagonists
Use of regular nebulisers
Continuous parenteral terbutaline infusions
Continuous intravenous aminophylline infusions
Anti-IgE immunoglobulin therapy
Steroid sparing agents, e.g. methotrexate, azathioprine, gold,
cyclophosphamide, mycophenylate
No relevance to difficult asthma
1 Fungal growth/identification on sputum culture
C.O. Prys-Picard et al.1258inadequately self-manage or are under perceivers
of asthma severity.24,25 It is believed that these
patients have ongoing airway inflammation and
reactivity and are susceptible to high risk asthma
attacks while not reporting or experiencing symp-
toms. In reality these patients do have severe
asthma, and are at risk of emergency healthcare
resource usage, but do not complain of an ‘appro-
priate’ level of symptomatology, and as such, lie
outside the consensus definition derived here. They
do however remain within the broader concept of
difficult asthma. The identification and manage-
ment of this group of patients remains of major
importance with specific reference to the preven-
tion of high-risk asthma events.
In patients with difficult asthma, identifying any
co-morbid condition that exists with asthma is
central to symptom reduction. Unfortunately, in
this group of patients, history, physical signs andphysiological parameters are often unhelpful
and sometimes misleading. By maintaining a high
degree of clinical suspicion and by following a
standardised and methodical investigational pro-
cess, it is hoped that therapy will match true
asthma severity, co-morbid conditions will be
treated appropriately, iatrogenic morbidity re-
duced and healthcare usage rationalised.Severe versus difficult asthma
All patients with severe persistent asthma as
defined by GINA will also fall under the category
of difficult asthma. In that respect, the definitions
are similar. The important differentiator is that in
difficult asthma, the symptom level rating may be
artificially high due to the presence of another
unrecognised condition, and the treatment level
inflated due to lack of efficacy.
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Table 4 Investigations that are necessary for patients with difficult asthma.
Median panel score
Absolute necessity in all patients
9 Assessment of environment/occupation
Assessment of psychological well-being
Must be available for assessment tool
8 Peak flow patterns/variability
Flow/volume loop
Assessment of compliance with medication
Plain chest radiograph
Assessment for vocal cord dysfunction
Assessment of dysfunctional breathing/hyperventilation
7 Spirometry with reversibility
Bronchial hyper-reactivity (PC20)
Skin prick testing
Blood eosinophilia
Total IgE estimation
Allergen specific RAST
HRCT chest
Arterial Blood Gas estimation in acute presentation for documentation
of type II respiratory failure
Assessment of smoking status
Assessment of medication side-effects
Assessment of Body Mass Index
Diffusion capacity (KCO)
Total lung capacity (TLC)
Assessment of corticosteroids efficacy
Bone densiometry
Table 5 Investigations that should be available, but are not necessary, for all patients with difficult asthma.
Median panel score
May be useful but not a necessity
4,5,6 Oesophageal pH monitoring for GORD
Arterial blood gas estimation for PO2, pH or PCO2
Inductance plethysmography
Food exclusion diet
Induced sputum differential white cell count
Exhaled nitric oxide (eNO)
CT sinuses
Bronchoscopy
Endo-bronchial biopsy
Lavage for differential white cell count
ENT assessment
Trial IM Triamcinolone in non-compliant/non-absorbant patients
Assessment of OSA (Epworth+overnight oximetry)
Exercise induced bronchospasm
Defining and investigating difficult asthma: Developing quality indicators 1259Investigation of difficult asthma
This study has developed a set of investigations
deemed necessary for the initial investigation of
difficult asthma. Investigation is aimed at confirm-
ing or excluding asthma and identifying other co-
morbid conditions. The incidence of the latter is
high in difficult asthma.The findings from an integrated approach to
investigating difficult asthma patients5,13 has con-
firmed the high incidence of additional diagnoses.
This study has provided a framework for the
detection of co-morbid pathology in these patients.
Measures developed using consensus techniques
have high face validity. Subsequent developmental
ARTICLE IN PRESS
Table 6 Investigations that are not routinely
necessary for the investigation of patients with
difficult asthma.
Median panel score
Not routinely required for
assessment
2,3 Inhaled allergen
challenge
Oral/nasal aspirin
challenge
Thyroid function
Assessment of
corticosteroid
absorption
Exhaled breath
condensate analysis
Progressive exercise
test
No relevance to difficult
asthma assessment
1 None
C.O. Prys-Picard et al.1260work is required to provide empirical evidence, as
far as is possible, to test for acceptability,
feasibility, reliability, sensitivity to change and
validity of the measures.17
The challenge when applying quality indicators is
that they tend to focus on care for populations or
average patients but they need also to reflect the
context and circumstances of individual patients.
Therefore, while the investigations rated as 47
should be conducted routinely for all patients, in
interpreting these findings, we propose that, as a
minimum requirement, a specialist difficult asthma
clinic would ideally have access to all the investi-
gations rated 4 or higher as listed in Tables 4 and 5.
These investigations provide a template for good
practice and for responding to individual patient
contexts. However, factors such as local availability
will cause disparity between these ‘ideals’ and
reality.
The definition of difficult asthma presented
here encompasses a larger proportion of asthma
patients than is currently seen in difficult or
severe asthma clinics. There may be a discrepancy
between clinical need and service provision
at present. Enabling greater patient access to
specialist services may require either expansion
of the number of centres or increasing the
capacity of the present ones. Since this group of
patients use a disproportionately high proportion
of the asthma healthcare budget11,12 it is reason-
able to expect that this will be a cost-effective
measure.Limitations
‘Difficult’ is a subjective term and its definition
with respect to asthma may vary between different
user groups. The panel was composed exclusively of
asthma specialists in the UK with responsibility for
running specialist asthma clinics. There was also no
patient involvement. The combined view on the
definition of difficult asthma is likely to be valid
elsewhere, but differences in health care systems
and daily practice between countries, partly
caused by national regulations, mean that investi-
gation protocols may need to be customised.26 The
definition of difficult asthma should apply as
equally to a paediatric population, but the relative
appropriateness of investigations may vary and has
not been addressed in this study.
There are no currently adequate freely available
methods for assessing compliance/concordance
with medication or corticosteroid efficacy. How-
ever, this study rated the necessity of investigations
required to provide quality care, not their current
feasibility.Conclusion
This paper formalises the conceptual definitions of
‘difficult’ as opposed to ‘severe’ asthma and
provides a list of clinical attributes required to
define difficult asthma. This is useful as a guide to
clinicians but also sets a standard to provide
uniformity in clinical trials. The central tenet is
that symptoms persist despite an arbitrarily defined
‘reasonable’ level of medication and they do so for
a number of disparate reasons. These persisting
symptoms may represent uncontrolled or unrespon-
sive severe asthma, or may be due to the presence
of other conditions. Appropriate therapy of the
latter may result in improvement or resolution of
the patients’ symptoms. The function of a difficult
asthma clinic is to bring together the appropriate
skills and facilities in a multi-disciplinary team to
evaluate a patient holistically, to confirm a
diagnosis of asthma and its severity and identify
other conditions and contributory factors which
otherwise make it ‘difficult’ to treat.Reference
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